系统性红斑狼疮血栓形成的分子机制——一项系统综述
该系统综述遵循PRISMA声明,检索PubMed与Embase(无时间限制),从3747篇文献中纳入30项实验研究(多数为横断面SLE队列血样,另有一项动物研究和一项病例对照研究),识别出六种血栓形成机制,多数集中于自身抗体尤其是抗磷脂抗体(aPL)。
要点
- SLE患者诊断后血栓风险约30%,但 causative 机制知识缺口大且缺乏特异性抗血栓指南。
- 纳入30项研究,28项在偏倚风险评估中方法学质量稳健,识别出六种不同血栓作用机制。
- 多数研究集中于自身抗体尤其是aPL,aPL与其他自身抗体共享机制可能解释aPL阴性SLE患者血栓风险增加。
核心结论
- SLE相关血栓机制研究存在显著知识缺口,尤其补体系统作用;多数研究依赖横断面设计,需前瞻性队列研究评估临床因素;缺乏综合研究考察多种促凝因素相互作用及其与血栓的关联。
研究设计与样本
- 系统综述遵循PRISMA声明,检索PubMed与Embase无时间限制,从3747篇初检文献中纳入30项研究,采用预设评估工具进行偏倚风险评估。
主要发现
- 纳入研究为实验性研究,使用横断面SLE队列血样,除一项动物研究和一项病例对照研究外。
- 识别出六种不同的血栓作用机制。
- 多数研究集中于自身抗体,以aPL为主;aPL与其他自身抗体之间的共享机制可能解释aPL阴性SLE患者血栓风险增加。
- 补体系统在SLE相关血栓中的作用存在显著知识缺口。
临床怎么用
- 原文未据此给出推荐。
局限性
- 多数研究依赖横断面设计,强调需要前瞻性队列研究以更好地评估临床因素。
- 补体系统在SLE相关血栓中的作用存在显著知识缺口。
- 缺乏综合研究考察多种促凝因素之间的相互作用及其与血栓的关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with systemic lupus erythematosus (SLE) face an approximately 30 % risk of thrombosis post-diagnosis. However, there remains significant knowledge gaps regarding causative mechanisms, and there is a lack of specific antithrombotic guidelines. This systematic review aims to examine the existing literature regarding the mechanisms contributing to thrombosis risk in SLE, focusing on five predefined procoagulant domains: autoantibodies (including antiphospholipid antibodies (aPL)), the complement system, platelets, the endothelium, and the coagulation system. The review followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statements and searched in PubMed and Embase without time restrictions. Risk of bias assessment was performed using a pre-specified evaluation tool. Out of 3,747 initially identified publications, 30 studies were included, with 28 demonstrating robust methodological quality in the risk of bias assessment. The studies were experimental, involving blood samples from cross-sectional SLE cohorts, except one animal -and one case-control study. We identified six different thrombosis mechanisms of action. Most studies concentrated on autoantibodies, predominantly aPL. Shared mechanisms between aPL and other autoantibodies may account for the increased thrombosis risk in aPL-negative SLE patients. Significant knowledge gaps remain, particularly regarding the role of the complement system in SLE-related thrombosis. Also, most research relies on cross-sectional designs, emphasizing the need for prospective cohort studies to better assess clinical factors. Finally, comprehensive studies examining the interactions between multiple procoagulant factors and their link to thrombosis are lacking. Closing these gaps in future research could improve both preventive and personalized treatment strategies for thrombosis in SLE.
引用
- Larsen ML, Nørgaard L, Linge P, et al. Molecular mechanisms underlying thrombosis in systemic lupus erythematosus - A Systematic review. Semin Arthritis Rheum. 2025. PMID: 40086157. doi:10.1016/j.semarthrit.2025.152707
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。